Primary breast non-Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors

American Journal of Hematology

Volumn 84, Issue 3, 2009, Pages 133-139

  Validire, Patricia ^a   Capovilla, Mathieu ^a   Asselain, Bernard ^a   Kirova, Youlia ^a   Goudefroye, Rémi ^a   Plancher, Corine ^a   Fourquet, Alain ^a   Zanni, Manuela ^a   Gaulard, Philippe ^b   Vincent Salomon, Anne ^a   Decaudin, Didier ^a  

^a INSTITUT CURIE   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 62949207156     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21353     Document Type: Article

References (49)

1. Dobrotina AF, Zlotnikova ZB. Generalized sarcomatosis (lymphosarcomatosis) in pregnancy with unusual bilateral involvement of the breasts. Vopr Onkol 1959;5:613-616.
2. Mattia AR, Ferry JA, Harris NL. Breast lymphoma. A B-cell spectrum including the low grade B-cell lymphoma of Mucosae Associated Lymphoid Tissue. Am J Surg Pathol 1993;17:574-587.
3. Ha C, Dubey P, Goyal L, et al. Localized primary non-Hodgkin's lymphoma of the breast. Am J Clin Oncol 1998;21:376-380.
4. Topalovski M, Crisan D, Mattason JC. Lymphoma of the breast. A clinicopath-ologic study of primary and secondary cases. Arch Pathol Lab Med 1999; 123:1208-1218.
5. Domchek SM, Hecht JL, Fleming MD, et al. Lymphomas of the breast. Primary and secondary involvement. Cancer 2002;94:6-13.
6. Yaqoob N, Pervez S, Kayani N, et al. Frequency and characteristics of breast lymphomas presenting to a tertiary care hospital, Pakistan. J Pak Med Assoc 2006;56:441-443.
7. Cohen PL, Brooks JJ. Lymphomas of the breast. A clinicopathologic and immunohistochemical study of primary and secondary cases. Cancer 1991;67:1359-1369.
8. Arber DA, Simpson JF, Weiss LM, Rappaport H. Non-Hodgkin's lymphoma involving the breast. Am J Surg Pathol 1994;18:288-295.
9. Gholam D, Bibeau F, El Weshi A, et al. Primary breast lymphoma. Leukemia Lymphoma 2003;44:1173-1178.
10. Lyons J, Myles J, Pohlman B, et al. Treatment and prognosis of primary breast lymphoma: A review of 13 cases. Am J Clin Oncol 2000;23:334-336.
11. Dixon JM, Lumsden AB, Krajewski A, et al. Primary lymphoma of the breast. Br J Surg 1987;74:214-216.
12. Ariad S, Lewis D, Cohen R, Bezwoda WR. Breast lymphoma. A clinical and pathological review and 10-year treatment results. S Afr Med J 1995;85:85-89.
13. Abbondanzo SL, Seidman JD, Lefkowitz M, et al. Primary diffuse large B-cell lymphoma of the breast. A clinicopathologic study of 31 cases. Path Res Pract 1996;192:37-43.
14. Sabaté JM, Gomez A, Torrubia S, et al. Lymphoma of the breast: Clinical and radiologic features with pathologic correlation in 28 patients. Breast J 2002;8:294-304.
15. Vignot S, Ledoussal V, Nodiot P, et al. Non-Hodgkin's lymphoma of the breast: A report of 19 cases and a review of the literature. Clin Lymphoma 2005;6:37-42.
16. Choo SP, Lim ST, Wong EH, Tao M. Breast lymphoma: Favorable prognosis after treatment with standard combination chemotherapy. Onkologie 2006;29:14-18.
17. Lin Y, Guo XM, Shen KW, et al. Primary breast lymphoma: Long-term treatment outcome and prognosis. Leuk Lymphoma 2006;47:2102-2109.
18. Ryan GF, Roos DR, Seymour JF. Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. Clin Lymphoma Myeloma 2006;6:337-341.
19. Aviles A, Castaneda C, Neri N, et al. Rituximab and dose dense chemotherapy in primary breast lymphoma. Haematologica 2007;92:1147-1148.
20. Cao YB, Wang SS, Huang HQ, et al. Primary breast lymphoma-A report of 27 cases with literature review. Ai Zheng 2007;26:84-89.
21. Ganjoo K, Advani R, Mariappan MR, et al. Non-Hodgkin lymphoma of the breast. Cancer 2007;110:25-30.
22. Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lym-phoma of the breast: Prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 2008;19:233-241.
23. Yoshida S, Nakamura N, Sasaki Y, et al. Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol 2005;18:398-405.
24. Maounis N, Ellina E, Papadaki T, et al. Bilateral primary lymphoma of the breast: A case report initially diagnosed by FNAC. Diagn Cytopathol 2005;32:114-118.
25. Hermine O, Haioun C, Lepage E, et al. prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lym-phomes de l'Adulte (GELA). Blood 1996;87:265-272.
26. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of Bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation study. Blood 1996;88:1046-1051.
27. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:244-251.
28. Barrans SL, Carter I, Owen RG, et al. germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99:1136-1143.
29. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes Bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-4284.
30. Sohn SK, Jung JT, Kim DH, et al. prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. Am J Hematol 2003;73:101-107.
31. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
32. Berglund M, Thunberg U, Amini RM, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005;18:1113-1120.
33. Biasoli I, Morais JC, Scheliga A, et al. CD10 and Bcl-2 expression combined with the International prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses. Histopa-thology 2005;46:328-333.
34. Zinzani PL, Dirnhofer S, Sabattini E, et al. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica 2005;90:341-347.
35. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B-cell lymphoma. J Pathol 2006;208:714-723.
36. Shivakumar L, Armitage JO. Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma 2006;6:455-457.
37. Van Imhoff GW, Boerma EJG, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006;24:4135-4142.
38. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006;20:319-332.
39. Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study group. J Clin Oncol 2003;21:20-27.
40. Harris NL, Jaffe ES, Diébold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3855-3849.
41. Oken MM, Creech RH, Tormay DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
42. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodg-kin's disease staging classification. Cancer Res 1971;31:1860-1861.
43. A predictive model for aggressive non-Hodgkin's lymphoma: The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993;329:987-994.
44. Dumont J, Charpy-Validire P, Mosseri V, et al. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma. Hematol Oncol 1991;9:197-207.
45. Campana F, Kirova YM, Rosenwald JC, et al. Breast radiotherapy in the lateral decubitus position-A technique to prevent lung and heart irradiation. Int J Radiat Oncol Biol Phys 2005;61:1348-1354.
46. Kirova YM, Servois V, Campana F, et al. CT-scan based localization of the internal mammary chain and supraclavicular nodes for breast cancer radiation therapy. Radiother Oncol 2006;79:310-315.
47. Cheson BD, Horning JS, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-1253.
48. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
49. Cox DR. Regression models and life tables. J Roy Stat Soc 1972;34:187-220.